ClinicalTrials.gg
CompletedNCT05007392Updated Jul 30, 2025Results posted

A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout

A Phase 3 interventional study of Dotinurad and Febuxostat in Gout, sponsored by Eisai Co., Ltd.. Completed at 30 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Eisai Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
451
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing dotinurad in Gout — 4 open to participants now, 4 under way, 1 of them phase 3. dotinurad · Gout.

Enrollment
2nd of 10
451 · median 202
Started
2021
the only one that year
Phase 3
5 of 10
1 open now
Registered
5th of 10
by date
Lead sponsor
1 of 10
Eisai Co., Ltd.

Among the 10 studies testing dotinurad in Gout, this one is the 2nd largest by enrollment, is the only one that started in 2021, is one of 5 in phase 3, and was the 5th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

4 of the 10 studies testing dotinurad in Gout are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About dotinurad

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing dotinurad in Gout, or all of them as a file.
02

Study summary

The primary purpose of the study is to confirm the efficacy of dotinurad 4 milligram (mg) to febuxostat 40 mg on the percentage of participants achieving a serum uric acid (SUA) level less than or equal to (\<=) 6.0 milligrams per deciliter (mg/dL) at Week 24 in Chinese participants with gout.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • Dotinurad
  • Febuxostat
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gout participant (with a history of gout attack or concurrent gouty tophi) with SUA level greater than (>) 7.0 mg/dL in the screening phase (within 14 days prior to randomization)
  2. Male or female participant with age greater than or equal to (>=) 18 years at the time of
  3. Provide written informed consent signed by the participant prior to entering the study or undergoing any study procedures, indicating that they understand the purpose and procedures required for the study and are willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Has gouty arthritis that has not resolved within 14 days prior to randomization
  2. Has secondary hyperuricemia
  3. Comorbidities with nephrolithiasis or clinical urinary calculi (example, haematuria, back pain)
  4. Evidence of disease (example, cardiac disease: heart failure and angina unstable, respiratory, gastrointestinal, renal, or neurological disease: cerebral infarction) that in the opinion of the investigator could affect the participant's safety or interfere with the study assessments
  5. Evidence of clinical significant hepatic disease: refer to Grade 2 in the "Seriousness Grading Criteria for Adverse Drug Reactions" or (AST) or alanine aminotransferase (ALT) >3 multiple (*) (ULN) in the screening phase
  6. Estimated (eGFR) of less than (\<) 30 milliliter per minute/1.73 square meters in the screening phase
  7. Systolic blood pressure of >=180 millimetre of mercury (mmHg) or diastolic blood pressure of >=110 mmHg in the screening phase
  8. National Glycohemoglobin Standardization Program (NGSP) value of >=8.4 percent (%) in the screening phase
  9. to the study drugs (dotinurad or febuxostat) or their , or all of urine alkalinizer (potassium citrate/sodium citrate hydrate compound preparations)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
451 participants (actual)

Study arms

  • Experimental
    Drug: Dotinurad + Febuxostat Matched Placebo

    Participants will receive one dotinurad 1 mg tablet and one febuxostat 20 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then one dotinurad 2 mg tablet and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two dotinurad 2 mg tablets and two febuxostat 20 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).

    Drug: Dotinurad · Other: Febuxostat Matched Placebo

  • Active comparator
    Drug: Febuxostat + Dotinurad Matched Placebo

    Participants will receive one febuxostat 20 mg tablet and one dotinurad 1 mg matched placebo tablet, orally, once daily on Day 1 to Day 28 (up to 4 weeks) in Treatment 1 Phase; and then two febuxostat 20 mg tablets and one dotinurad 2 mg matched placebo tablet, orally, once daily on Day 29 to Day 84 (up to 8 weeks) followed by two febuxostat 20 mg tablets and two dotinurad 2 mg matched placebo tablets, orally, once daily on Day 85 to Day 168 (up to 12 weeks) in Treatment 2 Phase (Treatment 1 Phase=4 weeks; Treatment 2 Phase=20 weeks).

    Drug: Febuxostat · Other: Dotinurad Matched Placebo

Interventions

  • Dotinurad oral tablets.

    Also known as: FYU-981

  • Febuxostat oral tablets.

  • OtherDotinurad Matched Placebo

    Dotinurad matched placebo oral tablets.

  • OtherFebuxostat Matched Placebo

    Febuxostat matched placebo oral tablets.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF)

    Percentage of participants with SUA level less than or equal to (\<=) 6.0 milligrams per deciliter (mg/dL) at Week 24 was reported. In case the SUA level was missing, this data was compensated by the last observation carried forward (LOCF) method.

    Time frame: At Week 24

Secondary outcomes

  1. Percentage of Participants With SUA Level <=6.0 mg/dL at Week 12 (LOCF)

    Percentage of participants with SUA level \<=6.0 mg/dL at Week 12 was reported. In case the SUA level was missing, this data was compensated by the LOCF method.

    Time frame: At Week 12

  2. Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24

    Percentage of participants with SUA level \<=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 was reported. Data was reported for observed participants at specified visits.

    Time frame: At Weeks 4, 8, 12, 16, 20 and 24

  3. Mean Percent Reduction From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24

    Mean percent reduction from baseline in SUA level at Weeks 4, 8, 12, 16, 20 and 24 was reported.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  4. Mean Change From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24

    Mean change from baseline in SUA level at Weeks 4, 8, 12, 16, 20 and 24 was reported.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

  5. Mean SUA Level at Baseline, Weeks 4, 8, 12, 16, 20 and 24

    Mean SUA level at Baseline, Weeks 4, 8, 12, 16, 20 and 24 was reported.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24

07

Results

Posted Jul 30, 2025

Participant flow

Participants took part in the study at 30 investigative sites in China from 21 December 2021 to 14 June 2023.

Participant flow — Overall Study
MilestoneFebuxostatDotinurad
Started226225
Safety analysis set225223
Full analysis set220221
Completed197195
Not completed2930
Withdrew: Randomized but not treated12
Withdrew: Other54
Withdrew: Lost to follow-up12
Withdrew: Serum uric acid (sua) level of <=2.0 milligram per deciliter (mg/dl) for 2 consecutive visits01
Withdrew: Use of prohibited concomitant drug11
Withdrew: Inadequate therapeutic effect or progression of disease10
Withdrew: Adverse event106
Withdrew: Participant choice510
Withdrew: Withdrawal of consent54

Outcome measures

PrimaryPercentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF)

Percentage of participants with SUA level less than or equal to (\<=) 6.0 milligrams per deciliter (mg/dL) at Week 24 was reported. In case the SUA level was missing, this data was compensated by the last observation carried forward (LOCF) method.

Time frame:
At Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF)
percentage of participantsFebuxostatDotinurad
Percentage of Participants With Serum Uric Acid (SUA) Level <=6.0 mg/dL at Week 24 (LOCF)38.1 (31.6 to 44.5)73.6 (67.8 to 79.5)
Statistical analysis
  • Febuxostat vs Dotinurad · Cochran-Mantel-Haenszel · p = <0.001 · Difference of percentage: 35.87 · 95% CI 27.36 to 44.37The difference of percentage and stratified 95 percent (%) confidence interval (CI) was based on Mantel-Haenszel method.
SecondaryPercentage of Participants With SUA Level <=6.0 mg/dL at Week 12 (LOCF)

Percentage of participants with SUA level \<=6.0 mg/dL at Week 12 was reported. In case the SUA level was missing, this data was compensated by the LOCF method.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With SUA Level <=6.0 mg/dL at Week 12 (LOCF)
percentage of participantsFebuxostatDotinurad
Percentage of Participants With SUA Level <=6.0 mg/dL at Week 12 (LOCF)50.5 (43.8 to 57.1)55.5 (48.9 to 62.0)
Statistical analysis
  • Febuxostat vs Dotinurad · Difference of percentage: 5.24 · 95% CI -3.69 to 14.17The difference of percentage and stratified 95% CI was based on Mantel-Haenszel method.
SecondaryPercentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24

Percentage of participants with SUA level \<=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24 was reported. Data was reported for observed participants at specified visits.

Time frame:
At Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With SUA Level <=6.0 mg/dL at Weeks 4, 8, 12, 16, 20 and 24
percentage of participantsFebuxostatDotinurad
Week 426.327.6
Week 855.662.7
Wee 1252.856.9
Week 1648.784.7
Week 2053.783.0
Week 2440.278.1
SecondaryMean Percent Reduction From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24

Mean percent reduction from baseline in SUA level at Weeks 4, 8, 12, 16, 20 and 24 was reported.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Mean · Percent change in SUA level
Mean Percent Reduction From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24
Percent change in SUA levelFebuxostatDotinurad
Percent Reduction from Baseline at Week 426.43 ± 13.20027.43 ± 14.754
Percent Reduction from Baseline at Week 837.06 ± 14.01839.10 ± 18.931
Percent Reduction from Baseline at Week 1236.06 ± 15.38338.62 ± 17.305
Percent Reduction from Baseline at Week 1635.13 ± 16.01651.47 ± 18.542
Percent Reduction from Baseline at Week 2035.71 ± 15.72850.22 ± 20.714
Percent Reduction from Baseline at Week 2432.28 ± 16.90748.07 ± 23.243
SecondaryMean Change From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24

Mean change from baseline in SUA level at Weeks 4, 8, 12, 16, 20 and 24 was reported.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Mean · mg/dL
Mean Change From Baseline in SUA Level at Weeks 4, 8, 12, 16, 20 and 24
mg/dLFebuxostatDotinurad
Change from Baseline at Week 4-2.60 ± 1.457-2.70 ± 1.508
Change from Baseline at Week 8-3.62 ± 1.597-3.80 ± 1.973
Change from Baseline at Week 12-3.52 ± 1.691-3.78 ± 1.817
Change from Baseline at Week 16-3.44 ± 1.731-5.05 ± 2.078
Change from Baseline at Week 20-3.52 ± 1.757-4.92 ± 2.201
Change from Baseline at Week 24-3.20 ± 1.800-4.71 ± 2.415
SecondaryMean SUA Level at Baseline, Weeks 4, 8, 12, 16, 20 and 24

Mean SUA level at Baseline, Weeks 4, 8, 12, 16, 20 and 24 was reported.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20 and 24
Reported as:
Mean · mg/dL
Mean SUA Level at Baseline, Weeks 4, 8, 12, 16, 20 and 24
mg/dLFebuxostatDotinurad
Baseline9.65 ± 1.4269.67 ± 1.451
Week 47.07 ± 1.4326.93 ± 1.447
Week 86.01 ± 1.3725.80 ± 1.857
Week 126.12 ± 1.5465.88 ± 1.708
Week 166.24 ± 1.6054.65 ± 1.776
Week 206.14 ± 1.4674.76 ± 1.900
Week 246.49 ± 1.5755.00 ± 2.296

Adverse events

Collected over From first dose of study drug up to Week 24. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Febuxostat0/225 (0%)4/225 (1.8%)203/225 (90.2%)
Dotinurad0/223 (0%)3/223 (1.3%)201/223 (90.1%)
Most frequent serious events
Most frequent serious events
EventFebuxostatDotinurad
HaemorrhoidsGastrointestinal disorders0/2251/223
Inguinal herniaGastrointestinal disorders0/2251/223
Ankle fractureInjury, poisoning and procedural complications0/2251/223
Joint dislocationInjury, poisoning and procedural complications0/2251/223
Ligament injuryInjury, poisoning and procedural complications0/2251/223
CataractEye disorders1/2250/223
Meniscus injuryInjury, poisoning and procedural complications1/2250/223
Neoplasm skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2250/223
Glomerulonephritis membranousRenal and urinary disorders1/2250/223
Most frequent other events
Showing 10 of 240
Most frequent other events
EventFebuxostatDotinurad
Gouty arthritisMusculoskeletal and connective tissue disorders78/22597/223
COVID-19Infections and infestations57/22557/223
Alanine aminotransferase increasedInvestigations28/22518/223
Hepatic function abnormalHepatobiliary disorders18/22524/223
Upper respiratory tract infectionInfections and infestations22/22513/223
Alpha 1 microglobulin increasedInvestigations19/22512/223
SARS-CoV-2 test positiveInvestigations8/22517/223
NephrolithiasisRenal and urinary disorders17/22514/223
HyperlipidaemiaMetabolism and nutrition disorders13/22516/223
Blood creatine phosphokinase increasedInvestigations15/2258/223

Baseline characteristics

Full Analysis Set was the group of randomized participants who received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement.

Age, Continuous
Age, Continuous(years)FebuxostatDotinuradTotal
Mean39.2 ± 10.9838.9 ± 11.5639.1 ± 11.26
Sex: Female, Male
Sex: Female, Male(Participants)FebuxostatDotinuradTotal
Female538
Male215218433
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FebuxostatDotinuradTotal
Hispanic or Latino000
Not Hispanic or Latino220221441
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FebuxostatDotinuradTotal
American Indian or Alaska Native000
Asian220221441
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

30 sites
  • Anhui Provincial Hospital
    Hefei, Anhui 230001, China
  • Beijing Anzhen Hospital,Capital Medical University
    Beijing, Beijing Municipality 100029, China
  • Beijing Hospital
    Beijing, Beijing Municipality 100034, China
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • Beijing Tongzhou District Luhe Hospital, Beijing, P.R.China
    Beijing, Beijing Municipality 101100, China
  • Foshan First People's Hospital
    Foshan, Guangdong 528000, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong 510080, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong 510280, China
  • Jieyang People's Hospital
    Jieyang, Guangdong, China
  • The Seventh Affiliated Hospital of Sun Yat-sen University
    Shenzhen, Guangdong 200090, China
  • Shenzhen People's Hospital
    Shenzhen, Guangdong 518020, China
  • Hainan General Hospital
    Haikou, Hainan 570311, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hu'nan 410013, China
  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
    Wuhan, Hubei 430030, China
  • First Affiliated Hospital of Inner Mongolia technological University
    Baotou, Inner Mongolia 14010, China
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia 10050, China
  • The First People's Hospital of Changzhou
    Changzhou, Jiangsu 210300, China
  • Nanjing Medical University Affiliated 2nd Hospital
    Nanjing, Jiangsu 210011, China
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu 225000, China
  • Jiangxi Pingxiang People's Hospital
    Pingxiang, Jiangxi 337055, China
  • Jilin Province People's Hospital
    Changchun, Jilin 130021, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Yanbian University Hospital
    Yanji, Jilin 133000, China
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116011, China
  • Dalian Municipal Central Hospital Affiliated of Dalian Medical University
    Dalian, Liaoning 116021, China
  • The Second Hospital of Dalian Medical University
    Dalian, Liaoning 116023, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
  • Tong Ren Hospital Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200050, China
  • Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
    Shanghai, Shanghai Municipality 200052, China
  • The First People's Hospital of Yunnan Province
    Kunming, Yun'nan 650032, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jun 2023, 17 months.

Results were first posted in Jul 2025, 2 years 1 month after primary completion.

Of 21 phase 3 interventional studies under Gout, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 25. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2021
First posted
Aug 16, 2021
StartActual
Dec 21, 2021
Primary completionActual
Jun 14, 2023
CompletionActual
Jun 14, 2023
Results first posted
Jul 30, 2025
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05007392
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Aug 16, 2021
Start date
Dec 21, 2021
Primary completion
Jun 14, 2023
Completion
Jun 14, 2023
Results posted
Jul 30, 2025
Last update
Jul 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dotinurad

Start the discussion